Valneva rises after trial data for its chikungunya vaccine in children

Valneva SE

11/12/2025 09:06

** Shares in French vaccines company Valneva rise 5.8% after it reported phase 2 trial data for its IXCHIQ vaccine for chikungunya in children

** The group says it recorded a 94.7% seroresponse rate in children who have never been exposed to the Chikungunya virus (CHIKV) before at day 360

** "IXCHIQ was well tolerated in children aged 1-11 years regardless of the dose or previous CHIKV infection, supporting the selection of the full dose for use in this population," Kempen analysts say in a note

** Shares in Valneva are on track for their biggest daily gain since November 26, if gains hold

 (Reporting by Mathias de Rozario in Gdansk)

 ((mathias.derozario@tr.com))